Utilization of the multiple sclerosis functional composite as an outcome measure in the phase 3 trial of interferon beta-1a (Avonex®) in secondary progressive multiple sclerosis (IMPACT)

被引：0
|
作者：
Cohen, JA
Cutter, GC
Simonian, NA
Goodman, AD
Heidenreich, FR
Simon, JH
Whitaker, JN
机构：
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A548 / A549
页数：2
相关论文
共 50 条
  • [1] Results of IMPACT, a phase 3 trial of Interferon beta-1a in secondary progressive multiple sclerosis
    Cohen, JA
    Goodman, AD
    Heidenreich, FR
    Koojimans, MF
    Lull, JM
    Sandrock, AW
    Simon, JH
    Simonian, NA
    Whitaker, JN
    NEUROLOGY, 2001, 56 (08) : A148 - A149
  • [2] One-year change in the Multiple Sclerosis Functional Composite and expanded disability status scale in the phase 3 trial of interferon beta-1a in secondary progressive Multiple Sclerosis (IMPACT)
    Cohen, JA
    Cutter, GC
    Fischer, JS
    Goodman, AD
    Heidenreich, FR
    Lull, JM
    Sandrock, AW
    Simonian, NA
    Whitacre, JN
    Whitaker, JN
    NEUROLOGY, 2000, 54 (07) : A215 - A215
  • [3] Cerebrospinal fluid abnormalities in a phase III trial interferon beta-1a (Avonex) for relapsing multiple sclerosis
    Rudick, RA
    Cookfair, RD
    Ransohoff, R
    Jacobs, L
    Herndon, R
    Richert, J
    Salazar, A
    Fischer, J
    Granger, C
    Simon, J
    Goodkin, D
    ANNALS OF NEUROLOGY, 1996, 40 (03) : M104 - M104
  • [4] Interferon beta-1a in primary progressive multiple sclerosis
    Leary, SM
    Thompson, AJ
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 215 - 216
  • [5] The effect of natalizumab and interferon beta-1a on disability in secondary progressive multiple sclerosis
    Dzau, Winston
    Roos, Izanne
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1166 - 1167
  • [6] Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
    Gurevich, Michael
    Miron, Gadi
    Falb, Rina Zilkha
    Magalashvili, David
    Dolev, Mark
    Stern, Yael
    Achiron, Anat
    BMC NEUROLOGY, 2015, 15
  • [7] Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
    Michael Gurevich
    Gadi Miron
    Rina Zilkha Falb
    David Magalashvili
    Mark Dolev
    Yael Stern
    Anat Achiron
    BMC Neurology, 15
  • [8] Acute hepatitis secondary to interferon beta-1a in multiple sclerosis
    Christopher, V
    Scolding, N
    Przemioslo, R
    JOURNAL OF NEUROLOGY, 2005, 252 (07) : 855 - 856
  • [9] Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial
    Cohen, JA
    Cutter, GR
    Fischer, JS
    Goodman, AD
    Heidenreich, FR
    Jak, AJ
    Kniker, JE
    Kooijmans, MF
    Lull, JM
    Sandrock, AW
    Simon, JH
    Simonian, NA
    Whitaker, JN
    ARCHIVES OF NEUROLOGY, 2001, 58 (06) : 961 - 967
  • [10] Interferon beta for secondary progressive multiple sclerosis
    La Mantia, Loredana
    Vacchi, Laura
    Di Pietrantonj, Carlo
    Ebers, George
    Rovaris, Marco
    Fredrikson, Sten
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (01):
12345